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Polymorphisms in Apoptosis-Related Genes and TP53 Mutations 
in Non-Small Cell Lung Cancer
Apoptosis plays an essential role in the elimination of mutated or transformed cells from 
the body. Therefore, polymorphisms of apoptosis-related genes may lead to an alteration 
in apoptotic capacity, thereby affecting the occurrence of TP53 mutations in lung cancer. 
We investigated the relationship between potentially functional polymorphisms of 
apoptosis-related genes and TP53 mutations in non-small cell lung cancer (NSCLC). 
Twenty-seven single nucleotide polymorphisms in 20 apoptosis-related genes were 
genotyped by a sequenome mass spectrometry-based genotyping assay in 173 NSCLCs and 
the associations with TP53 mutations in the entire coding exons (exons 2-11), including 
splicing sites of the gene, were analyzed. None of the 27 polymorphisms was significantly 
associated with the occurrence of TP53 mutations. This suggests that apoptosis-related 
genes may not play an important role in the occurrence of TP53 mutations in lung cancer.
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BRIEF COMMUNICATION
Oncology & Hematology
Environmental exposure, primarily cigarette smoke, is the most 
important risk factor for lung cancer. The genetic and epigene-
tic damage caused by environmental carcinogens is considered 
to be the major mechanism underlying the development of lung 
cancer (1). Somatic mutations of the TP53 gene are among the 
most frequent genetic alterations detected in lung cancer and 
occur in -50% of patients with non-small cell lung cancer (NSCLC) 
(2). TP53 mutations often occur in pre-neoplastic lesions and 
in histologically normal lung tissue surrounding the tumor (3). 
In addition, TP53 mutations have been reported to be associated 
with a poor prognosis, as well as with a poor response to chemo- 
and radio-therapy (4). Thus, TP53 mutations play an important 
role not only in the development and progression of NSCLC, but 
also in determining the therapeutic response. Therefore, identi-
fication of genetic factors related to the occurrence of TP53 mu-
tations would be help to find novel ways to prevent and manage 
lung cancer. In view of this point, several studies have shown that 
polymorphisms of the genes involved in xenobiotic metabolism 
and DNA repair are associated with the occurrence of TP53 mu-
tations (5-7).
  Apoptosis is a highly regulated process of cell death which con-
trols the cell number in multicellular organisms and eliminates 
unnecessary or damaged cells. It is assumed that a decreased 
ability to eliminate cells with DNA damage may facilitate the 
accumulation of somatic mutations, and thereby contribute to 
tumor initiation, progression, and metastasis (8). There is con-
siderable interindividual variation in apoptotic capacity, and 
such variation is largely attributed to an individual’s genetic con-
stitution (9). In addition, it has been reported that several poly-
morphisms in apoptosis-related genes affect the expression or 
activities of enzymes and therefore the polymorphisms are as-
sociated with the risk and prognosis of various human cancers, Bae EY, et al.  •  Polymorphisms in Apoptotic Genes and TP53 Mutations in Non-Small Cell Lung Cancer
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including lung cancer (10, 11). Therefore, it has been hypothe-
sized that an alteration in apoptotic capacity related to polymor-
phisms of apoptosis-related genes could affect the risk of TP53 
mutations in lung cancer. To test this hypothesis we investigat-
ed the relationship between polymorphisms of apoptosis-relat-
ed genes and TP53 mutations in NSCLCs. 
  Tumor and corresponding non-malignant lung tissue speci-
mens were provided by the National Biobank of Korea-Kyung-
pook National University Hospital, Daegu, Korea, which is sup-
ported by the Ministry of Health, Welfare and Family Affairs. The 
population used in the present study was evaluated previously 
for TP53 mutations (12). The patients underwent curative resec-
tion at Kyungpook National University Hospital from January 
2003 to July 2007 and registered collectively to the National Bio-
bank in April 2011. All materials derived from the National Bio-
bank were obtained under Institutional Review Board approved 
protocols (Approval No., KNUHBIO_10_1017). All of the patients 
included in this study were ethnic Koreans. Patients who under-
went chemotherapy or radiotherapy prior to surgery were ex-
cluded to avoid the effects on DNA. Of 176 patients in our previ-
ous study (12), three squamous cell carcinoma patients includ-
ing one harboring a TP53 mutation were excluded in the present 
study because of lack of available DNA. As a result, this study in-
cluded 56 patients with squamous cell carcinoma and 117 patients 
with adenocarcinoma. There were 113 males and 60 females in 
the study cohort. The patients consisted of 56 never-smokers 
and 117 smokers. Of the 117 patients with adenocarcinoma, 54 
were never-smokers. All of the tumor and macroscopically-nor-
mal lung tissue samples were obtained at the time of surgery, 
and rapidly frozen in liquid nitrogen, and stored at -80°C. Only 
tumors with greater than 80% of the tumor component were 
sent for analysis. This study was approved by the Institutional 
Review Board of Kyungpook National University Hospital. The 
methods and results of TP53 mutation analysis have been de-
scribed in our previous study (12). Briefly, TP53 mutations of 
the entire coding exons (exons 2-11), including the splicing sites 
of the gene, were examined using PCR-based sequencing. All 
sequence variants were confirmed by sequencing the products 
of independent PCR amplifications in both directions. Among 
173 tumors, there were two adenocarcinoma cases which had 
borderline height of minor peak for mutation positivity and were 
designated as wild-type TP53 in the previous study (12). Repeat-
ed sequencing was done using additional pieces of the same 
individual tumor samples to confirm the presence of TP53 mu-
tation. As a result, compared to our previous study (12), two more 
TP53 mutations were additionally confirmed in two adenocar-
cinoma patients. Somatic TP53 mutations were detected in 66 
of 173 tumors (38.2%). TP53 mutations were more frequent in 
males, ever-smokers, and patients with squamous cell carcino-
ma (50.4%, 51.3%, and 60.7%, respectively) than in females, nev-
er-smokers, and patients with adenocarcinoma (15.0%, 10.7%, 
and 27.4%, respectively; all comparisons, P < 0.001). However, 
the TP53 mutation status was not associated with age and patho-
logic stage of the disease. 
  Due to the high number of single nucleotide polymorphisms 
(SNPs) in the human genome, the initial challenge was the effi-
cient selection of potentially functional SNPs. Thus, a prioritiz-
ing strategy was created using public databases that provide di-
verse information on the potential phenotypic risks of SNPs. 
First, candidate genes involved in apoptosis and related infor-
mation were collected from web-based databases that included 
information on the biologic pathway and potential biologic effects 
of SNPs. Next, SNPs with minor allele frequencies < 0.10 were 
excluded based on the allele frequencies recorded for East Asian 
populations obtained from FASTSNP. The selected SNPs were 
then scored according to certain phenotypic risks, and ordered 
according to the sum of the risk scores based on the algorithm 
suggested by Yuan et al. (13). Finally, 28 polymorphisms in 20 
genes with high-risk scores were selected for study. Caspase8 
rs383412 was genotyped by PCR-RFLP assay and the remaining 
27 SNPs were genotyped using a sequenome mass spectrome-
try-based genotype assay. For quality control, the genotyping 
analysis was performed blind with respect to the patients. Ap-
proximately 10% of the samples were randomly selected to be 
genotyped again by PCR-restriction fragment length polymor-
phism or DNA sequencing. The Hardy-Weinberg equilibrium 
(HWE) was tested by comparing the observed and expected 
genotype frequencies using a goodness-of-fit chi-squared test. 
The association between genotypes and TP53 mutations was 
analyzed using the chi-squared test or Fisher’s exact test. The 
possible associations were evaluated by unconditional multi-
variate logistic regression models controlling for age, gender, 
smoking status, tumor histology and pathologic stage (odds ratio 
and 95% confidence interval) where appropriate. 
  Among the 28 polymorphisms genotyped, the BIRC5 rs207-
1214A > G SNP was shown to deviate from the HWE (P < 0.05), 
and was thus excluded from further analysis. The identification 
numbers, genotype and minor allele frequencies, genotyping 
call rates, and P values for the HWE of the remaining 27 poly-
morphisms are shown in Table 1. None of the 27 polymorphisms 
were significantly associated with the occurrence of TP53 mu-
tations under dominant, recessive, and codominant models 
(Table 1). 
  Apoptosis plays a critical role in the maintenance of genomic 
integrity by eliminating cells with un-repairable DNA damage 
(8). Thus, it is assumed that variation in apoptosis-related genes 
may influence the apoptotic capacity related to the elimination 
of DNA alterations, thereby modulating the occurrence of TP53 
mutations. In the present study, there was no significant associ-
ation between potentially functional polymorphisms in the apop-
tosis-related genes and the frequency of TP53 mutations. This 
is the first comprehensive study to use a multigenic analysis of Bae EY, et al.  •  Polymorphisms in Apoptotic Genes and TP53 Mutations in Non-Small Cell Lung Cancer
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apoptosis-related gene polymorphisms in relation to TP53 mu-
tations. However, a number of limitations in the present study 
need to be addressed. Our study was limited by the modest sam-
ple size, which did not have sufficient statistical power for the 
detection of variants that had a small effect on the occurrence 
of TP53 mutations; therefore, there might be type II errors. In 
addition, the sample size did not have sufficient statistical pow-
er to examine the associations between genotypes and specific 
types of TP53 mutations, such as G:C > T:A transversions and 
G:C > A:T transitions at CpG sites. Therefore, additional studies 
with larger sample sizes are required. 
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Table 1. TP53 mutations by genotypes of apoptosis-related gene polymorphisms
Genes Polymorphism*
CR (%) MAF HWE P
Mutation by genotypes, n/N
† Adjusted OR (95% CI)
¶
Symbol  
(Alias)
ID no.
Base (AA)  
change
WW WV VV P
‡ Dominant Recessive Codominant
TNFSF1 
(LTA)
rs1041981 C > A (T60N) 95.4 0.43 0.53 22/51 30/85 11/29 0.66 0.75 (0.35-1.60) 0.92 (0.37-2.31) 0.86 (0.52-1.43)
TNFSF6 
(FASL)
rs763110 -844C > T 93.6 0.25 0.80 32/91 24/60 5/11 0.72 1.21 (0.60-2.47) 1.07 (0.28-4.16) 1.14 (0.65-2.01)
TNFSF10
(TRAIL)
rs3136586 -489A > G 95.4 0.51 0.19 12/42 29/74 18/47 0.39 1.62 (0.71-3.72) 0.96 (0.44-2.09) 1.16 (0.72-1.85)
TNFRSF1A
(TNFR1)
rs4149570 -329G > T 95.4 0.39 0.80 26/62 26/77 10/26 0.61 0.75 (0.35-1.60) 0.92 (0.37-2.31) 0.86 (0.52-1.43)
TNFRSF1B
(TNFR2)
rs1061622 T > G (M196R) 96.0 0.15 0.52 48/120 15/41 1/5 0.64 0.70 (0.32-1.52) 0.58 (0.05-6.94) 1.18 (0.32-4.32)
rs1061624 *188G > A 94.8 0.39 0.44 26/58 32/83 6/23 0.29 1.03 (0.50-2.13) 0.67 (0.23-1.98) 0.92 (0.54-1.57)
TNFRSF6
(FAS)
rs10788624 -4403T > C 91.3 0.41 0.09 27/61 22/66 14/31 0.36 0.80 (0.38-1.68) 0.91 (0.36-2.30) 0.89 (0.55-1.44)
rs2234767 -1377G > A 97.7 0.43 0.33 21/52 32/89 12/28 0.76 1.00 (0.48-2.10) 1.07 (0.42-2.72) 1.02 (0.62-1.69)
rs1800682 -670A > G 98.3 0.47 0.50 19/46 30/89 15/35 0.53 0.98 (0.45-2.13) 1.03 (0.44-2.44) 1.00 (0.61-1.64)
TNFRSF10B
(DR5)
rs1047266 C > T (A67V) 98.3 0.22 0.36 36/102 26/62 2/6 0.68 1.20 (0.59-2.41) 1.32 (0.19-9.37) 1.18 (0.64-2.19)
CASP10 rs13006529 T > A (L522I) 98.3 0.20 0.64 44/109 19/53 3/8 0.86 0.79 (0.39-1.62) 0.79 (0.16-3.96)    0.83 (0.46-1.50)
CASP9 rs4645978 -1263A > G 100.0 0.40 0.97 23/63 34/83 9/27 0.73 1.61 (0.79-3.30) 0.89 (0.34-2.35) 1.23 (0.74-2.20)
rs4645981 -712C > T 95.4 0.22 0.89 41/99 20/58 1/8 0.22 0.95 (0.45-1.99) 0.21 (0.02-1.98) 0.81 (0.44-1.52)
rs1052571 T > C (V28A) 97.7 0.40 0.97 22/62 33/81 8/26 0.62 0.73 (0.36-1.48) 0.82 (0.20-3.35) 0.79 (0.45-1.39)
CASP8 rs3834129 -652 6N del 99.4 0.23 0.77 42/102 20/60 4/10 0.61 0.67 (0.33-1.36) 0.74 (0.18-3.10) 0.74 (0.42-1.30)
rs3769818 IVS12-19C > T 97.7 0.28 0.61 29/86 29/71 5/12 0.62 1.27 (0.63-2.56) 0.95 (0.27-3.39) 1.15 (0.66-1.99)
CASP7 rs11593766 T > G (D4E) 98.8 0.11 0.10 53/133 12/38 0/0 0.35 0.55 (0.24-1.30) - 0.55 (0.24-1.30)
rs2227310 C > G (D255E) 97.1 0.40 0.72 23/59 30/83 12/26 0.66 0.72 (0.34-1.53) 1.12 (0.44-2.81) 0.89 (0.54-1.48)
CASP3 rs2705897 IVS5-4T > G 97.1 0.20 0.88 39/108 22/53 2/7 0.71 1.20 (0.58-2.49) 1.82 (0.24-13.8) 1.22 (0.64-2.33)
APAF1 rs2289315 -529G > A 93.6 0.18 0.11 38/113 20/41 4/8 0.18 2.08 (0.96-4.50) 1.28 (0.28-5.85) 2.33 (0.65-8.29)
BCL2 rs2279115 -938C > A 96.5 0.42 0.33 20/60 32/75 12/32 0.54 1.31 (0.63-2.73) 0.84 (0.35-2.01) 1.07 (0.66-1.72)
BID rs8190315 A > G (S56G) 96.0 0.09 0.68 52/136 12/29 0/1 0.69 0.97 (0.40-2.38) - 0.96 (0.40-2.30)
BIRC5 
(Survivin)
rs9904341 91C > G 98.8 0.49 0.32 21/47 28/79 15/45 0.47 0.57 (0.26-1.26) 0.74 (0.33-1.66) 0.72 (0.44-1.18)
BRACA1
(BRCC1)
rs799917 C > T (P817L) 95.4 0.32 0.63 24/74 31/75 6/16 0.53 1.58 (0.77-3.22) 1.61 (0.47-5.52) 1.44 (0.83-2.51)
BRACA2
(BRCC2)
rs144848 T > G (N372H) 96.0 0.24 0.37 36/97 21/57 3/12 0.71 0.84 (0.41-1.72) 0.41 (0.10-1.71) 0.77 (0.44-1.35)
PTGS2
(COX2)
rs5275 *427T > C 90.2 0.18 0.91 43/104 12/47 3/5 0.10 0.46 (0.21-1.05)   2.10 (0.31-14.02) 0.64 (0.32-1.26)
TP53 rs1042522 G > C (R72P) 96.2 0.39 0.20 20/66 31/71 12/29 0.25 1.63 (0.79-3.37) 1.28 (0.52-3.18) 1.33 (0.82-2.16)
*Information about polymorphisms and IDs were obtained from NCBI database (http://www.ncbi.nlm.gov.SNP). In the reference sequence, the transcription start site was count-
ed as +1; 
†Number of cases with TP53 mutation/number of total cases; 
‡Two-sided χ2 test for the frequency of TP53 mutations according to genotypes; 
¶ORs, 95% CIs were 
calculated using multivariate regression analysis, adjusted age, gender, smoking status, tumor histology, and pathologic stage. AA, amino acid; CR, call rate; MAF, minor allele 
frequency; HWE, Hardy-Weinberg equilibrium; W, wild-type allele; V, variant allele; OR, odds ratio; CI, confidence interval; TNFSF, tumor necrosis factor superfamily; LTA, lym-
photoxin alpha; FASL, FAS ligand; TRAIL, TNFR apoptosis-inducing ligand; TNFRSF, TNF receptor superfamily; DR, death receptor, CASP, caspase; APAF1, Apoptotic peptidase 
activating factor 1; BCL2, B-cell CLL/lymphoma 2; BID, BH3 interacting domain death agonist; BIRC5, Baculoviral IAP repeat containing 5; BRACA1, breast cancer 1, early on-
set; PTGS2, prostaglandin-endoperoxide synthase 2; COX2, cyclooxygenase-2; TP53, tumor protein 53.Bae EY, et al.  •  Polymorphisms in Apoptotic Genes and TP53 Mutations in Non-Small Cell Lung Cancer
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